Valeritas (NSDQ:VLRX) touted positive findings today from an analysis of its V-Go wearable insulin delivery system with a weekly physician-driven insulin titration algorithm.
Two-thirds of patients met their glycemic targets, the company said, and patient-reported hypoglycemia dropped by the end of the study.
In adult patients with Type II diabetes prescribed V-Go, daily self-monitored blood glucose profiles were used to make weekly V-Go titration decisions.
Fifteen patients in the study were evaluated after four months of using V-Go, the company said, and an A1C target of 7.5% or lower was achieved in 67% of patients. Hypoglycemia prevalence dropped from 23% at baseline to 7% of patients after four months.
“This proof-of-concept study demonstrates that a simplified prandial or bolus focused weekly insulin titration algorithm in patients with Type II diabetes prescribed V-Go can be used effectively and safely, leading to significantly improved glycemic control while also lowering the mean total daily insulin dose of insulin,” president & CEO John Timberlake said in prepared remarks.
“The results are very promising and support the importance of addressing post prandial glucose to achieve glycemic targets.”
